Satsuma Pharmaceuticals, Inc. STSA
Set alert
1.10 +1.10 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 36.80M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -1.29
- Beta
- 0.10
- Short ratio
- 0.05
- Inst. own
- 57.90%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 11, 2023
- 50-d avg
- 0.991336
- 200-d avg
- 2.18
- 1y target
- 2.00
6M chart
Events in this range
- Mar 28, 2023Earnings: —; estimate -0.38; surprise —%
- Mar 30, 2023Rating: HC Wainwright & Co. · — → Buy
- Mar 30, 2023Rating: Mizuho · — → Neutral
- Apr 18, 2023Downgrade: HC Wainwright & Co. · Buy → Neutral
- May 11, 2023Earnings: —; estimate -0.26; surprise —%
Signals (16)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | May 11, 2023 | 3 years ago |
| SMA: Bullish | Apr 17, 2023 | 3 years ago |
| SMA: Bullish | Apr 17, 2023 | 3 years ago |
| MACD: Buy Signal | Apr 17, 2023 | 3 years ago |
| SMA: Bearish | Mar 8, 2023 | 3 years ago |
| MACD: Sell Signal | Mar 8, 2023 | 3 years ago |
| SMA: Bullish | Mar 7, 2023 | 3 years ago |
| SMA: Bearish | Mar 6, 2023 | 3 years ago |
| SMA: Bullish | Feb 24, 2023 | 3 years ago |
| SMA: Bearish | Feb 23, 2023 | 3 years ago |
| SMA: Bullish | Feb 14, 2023 | 3 years ago |
| MACD: Buy Signal | Feb 9, 2023 | 3 years ago |
| MACD: Sell Signal | Feb 8, 2023 | 3 years ago |
| SMA: Bearish | Feb 3, 2023 | 3 years ago |
| SMA: Bullish | Jan 24, 2023 | 3 years ago |
| RSI: Oversold | Dec 22, 2022 | 3 years ago |
Key statistics
- Market cap
- 36.80M
- Enterprise value
- -4.79M
- Trailing P/E
- 0.00
- Forward P/E
- -1.29
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.97
- EPS (TTM)
- -1.99
- Beta
- 0.10
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -24.91M
- Total cash
- 41.37M
- Total debt
- 116.00K
- Return on equity
- -104.04%
- Shares outstanding
- 33.15M
- Short % of float
- 0.74%
- 50-day average
- 0.991336
- 200-day average
- 2.18
Analyst view
Consensus: hold
Hold
Price target (mean) 2.00 +81.8% upside
Now 1.10
- Target (low)
- 1.00
- Target (mean)
- 2.00
- Target (high)
- 3.00
Next earnings
May 11, 2023
Expected May 11, 2023. Consensus EPS estimate -0.27.
Financials — quick view
STSA Revenue — quarterly 0
STSA Net income — quarterly -10.29M
STSA EPS — quarterly -0.31
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 11, 2023 | Mar 1, 2023 | -0.26 | — | — | — |
| Mar 28, 2023 | Dec 1, 2022 | -0.38 | — | — | — |
| Nov 3, 2022 | Sep 1, 2022 | -0.57 | — | — | — |
| Aug 9, 2022 | Jun 1, 2022 | -0.48 | — | — | — |
| May 10, 2022 | Mar 1, 2022 | -0.48 | — | — | — |
| Mar 15, 2022 | Dec 1, 2021 | -0.47 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 18, 2023 | HC Wainwright & Co. | down | Buy | Neutral |
| Mar 30, 2023 | Mizuho | reit | — | Neutral |
| Mar 30, 2023 | HC Wainwright & Co. | reit | — | Buy |
| Nov 15, 2022 | Mizuho | down | Buy | Neutral |
| Nov 15, 2022 | HC Wainwright & Co. | main | — | Buy |
| Nov 15, 2022 | SVB Leerink | down | Outperform | Market Perform |
About Satsuma Pharmaceuticals, Inc.
Satsuma Pharmaceuticals, Inc., a development-stage biopharmaceutical company, develops novel therapeutic products for the acute treatment of migraines. The company's product candidature includes STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. As of June 8, 2023, Satsuma Pharmaceuticals, Inc. operates as a subsidiary of Shin Nippon Biomedical Laboratories, Ltd.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- satsumarx.com
News
- Satsuma Pharmaceuticals Announces Presentation of Two Clinical Program Abstracts at the American Headache Society's 68th Annual Scientific Meeting
- Satsuma Pharmaceuticals and SNBL Announce Publication of Impression of Use and Satisfaction with STS101 (Dihydroergotamine Nasal Powder (Atzumi™)) in Headache
- Satsuma Pharmaceuticals and SNBL Announce Four Abstracts to be Presented at the American Headache Society's 67th Annual Scientific Meeting
- Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine
- Satsuma Pharmaceuticals and SNBL Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine With or Without Aura
- Satsuma Pharmaceuticals and SNBL Resubmits the New Drug Application for STS101 (Dihydroergotamine Nasal Powder) for the Acute Treatment of Migraine With or Without Aura
- Satsuma Pharmaceuticals and SNBL Announce Publication of STS101 (Dihydroergotamine Nasal Powder) Pivotal Phase 3 ASCEND Study in CNS Drugs
- Satsuma Pharmaceuticals and SNBL Announce Five Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society's 66th Annual Scientific Meeting
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- Why Universal Electronics Shares Are Trading Lower By 30%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Your note
Sign in to keep a note on STSA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALBRECHT DETLEF | Officer | Sale | Aug 31, 2020 | 20,212 |
| COMMODORE CAPITAL LP | Beneficial Owner of more than 10% of a Class of Security | Sale | Nov 13, 2022 | 0 |
| HADLEY HARBOR MASTER INVESTORS CAYMAN II, L.P. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Sep 16, 2019 | 1,105,150 |
| LEONARD BRADEN MICHAEL | Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 20, 2022 | 6,590,000 |
| O'NEIL THOMAS PAUL | Chief Financial Officer | Sale | Aug 31, 2020 | 0 |
| RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 25, 2021 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bml Capital Management, LLC | 19.43% | 6,440,000 | 7.08M | Mar 30, 2023 |
| RA Capital Management, L.P. | 17.84% | 5,914,252 | 6.51M | Mar 30, 2023 |
| NEA Management Company, LLC | 6.92% | 2,294,095 | 2.52M | Mar 30, 2023 |
| Vanguard Group, Inc. (The) | 2.78% | 920,517 | 1.01M | Mar 30, 2023 |
| Geode Capital Management, LLC | 1.25% | 414,344 | 455.78K | Mar 30, 2023 |
| Lion Point Capital, LP | 0.96% | 319,742 | 351.72K | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.58% | 522,516 | 574.77K | Dec 30, 2022 |
| Vanguard Extended Market Index Fund | 1.02% | 337,139 | 370.85K | Dec 30, 2022 |
| Fidelity NASDAQ Composite Index ETF | 0.66% | 217,688 | 239.46K | Mar 30, 2023 |
| Fidelity Extended Market Index Fund | 0.31% | 102,799 | 113.08K | Feb 27, 2023 |
| DFA U.S. Small Cap Series | 0.27% | 88,161 | 96.98K | Jan 30, 2023 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.20% | 65,000 | 71.50K | Dec 30, 2022 |